Home/Filings/4/0001209191-04-022845

4//SEC Filing

RIGEL PHARMACEUTICALS INC 4

Accession 0001209191-04-022845

$RIGLCIK 0001034842operating

View on SEC.gov Company Profile

Filed

Apr 29, 8:00 PM ET

Accepted

Apr 30, 1:48 PM ET

Size

21.2 KB

Accession

0001209191-04-022845

Insider Transaction Report

Form 4

Period: 2004-04-28

RIGEL PHARMACEUTICALS INCRIGL

ALTA EMBARCADERO BIOPHARMA PARTNERS II LLC

10% Owner

Transactions

Sale
Common Stock
2004-04-28$21.25/sh−7,821$166,196→ 490,774 total(indirect: See footnote)
Sale
Common Stock
2004-04-29$21.25/sh−34,023$723,002→ 456,751 total(indirect: See Footnote)
Sale
Common Stock
2004-04-29$21.25/sh−777$16,512→ 10,433 total(indirect: See Footnote)
Sale
Common Stock
2004-04-28$21.25/sh−179$3,804→ 11,210 total(indirect: See footnote)

Holdings

Common Stock
(indirect: See footnote)
44,573
Common Stock
(indirect: See footnote)
1,211,676

ALTA BIOPHARMA PARTNERS II LP

10% Owner

Transactions

Sale
Common Stock
2004-04-28$21.25/sh−7,821$166,196→ 490,774 total(indirect: See footnote)
Sale
Common Stock
2004-04-29$21.25/sh−777$16,512→ 10,433 total(indirect: See Footnote)
Sale
Common Stock
2004-04-28$21.25/sh−179$3,804→ 11,210 total(indirect: See footnote)
Sale
Common Stock
2004-04-29$21.25/sh−34,023$723,002→ 456,751 total(indirect: See Footnote)

Holdings

Common Stock
(indirect: See footnote)
1,211,676
Common Stock
(indirect: See footnote)
44,573

ALTA BIOPHARMA MANAGEMENT II LLC

10% Owner

Transactions

Sale
Common Stock
2004-04-29$21.25/sh−777$16,512→ 10,433 total(indirect: See Footnote)
Sale
Common Stock
2004-04-28$21.25/sh−7,821$166,196→ 490,774 total(indirect: See footnote)
Sale
Common Stock
2004-04-28$21.25/sh−179$3,804→ 11,210 total(indirect: See footnote)
Sale
Common Stock
2004-04-29$21.25/sh−34,023$723,002→ 456,751 total(indirect: See Footnote)

Holdings

Common Stock
(indirect: See footnote)
44,573
Common Stock
(indirect: See footnote)
1,211,676

CHAMPSI FARAH

Other

Transactions

Sale
Common Stock
2004-04-28$21.25/sh−7,821$166,196→ 490,774 total(indirect: See footnote)
Sale
Common Stock
2004-04-29$21.25/sh−34,023$723,002→ 456,751 total(indirect: See Footnote)
Sale
Common Stock
2004-04-28$21.25/sh−179$3,804→ 11,210 total(indirect: See footnote)
Sale
Common Stock
2004-04-29$21.25/sh−777$16,512→ 10,433 total(indirect: See Footnote)

Holdings

Common Stock
(indirect: See footnote)
44,573
Common Stock
(indirect: See footnote)
1,211,676

MARDUEL ALIX

Other

Transactions

Sale
Common Stock
2004-04-28$21.25/sh−7,821$166,196→ 490,774 total(indirect: See footnote)
Sale
Common Stock
2004-04-29$21.25/sh−34,023$723,002→ 456,751 total(indirect: See Footnote)
Sale
Common Stock
2004-04-28$21.25/sh−179$3,804→ 11,210 total(indirect: See footnote)
Sale
Common Stock
2004-04-29$21.25/sh−777$16,512→ 10,433 total(indirect: See Footnote)

Holdings

Common Stock
(indirect: See footnote)
44,573
Common Stock
(indirect: See footnote)
1,211,676

ALTA PARTNERS II INC

10% Owner

Transactions

Sale
Common Stock
2004-04-28$21.25/sh−7,821$166,196→ 490,774 total(indirect: See footnote)
Sale
Common Stock
2004-04-28$21.25/sh−179$3,804→ 11,210 total(indirect: See footnote)
Sale
Common Stock
2004-04-29$21.25/sh−34,023$723,002→ 456,751 total(indirect: See Footnote)
Sale
Common Stock
2004-04-29$21.25/sh−777$16,512→ 10,433 total(indirect: See Footnote)

Holdings

Common Stock
(indirect: See footnote)
1,211,676
Common Stock
(indirect: See footnote)
44,573

Footnotes (4)

[F1]Alta California Partners, L.P. ("ACP"): Jean Deleage, Director, is a general partner ("GP") of Alta California Mgmt. Partners, L.P. ("ACMP")(which is the GP of ACP) & a managing member of Alta Embarcadero Partners, LLC ("AEP"). Alta Partners ("AP") provides investment advisory services to several venture capital funds including ACP & AEP. The respective GP and members of ACP & AEP exercise sole voting & investment powers with respect to the shares owned by the funds. Jean Deleage, Garrett Gruener & Guy Nohra are general partners of ACMP, and Jean Deleage & Garrett Gruener are members of AEP (collectively known as the "principals"). As general partners & members, they may be deemed to share voting & investment powers over the shares owned by the foregoing funds. The principals disclaim beneficial ownership of all such shares held by the foregoing funds, except to the extent of their proportionate pecuniary interests therein.
[F2]Alta Embarcadero Partners, LLC: See footnote for Alta California Partners, L.P. on this Form 4.
[F3]Alta BioPharma Partners II, L.P. ("ABPII"): Jean Deleage, Director, is a managing director of Alta BioPharma Mgmt. Partners II, LLC ("ABMPII")(which is the General Partner ("GP") of ABPII) & a manager of Alta Embarcadero BioPharma Partners II, LLC ("AEBPII"). Alta Partners II, Inc. ("APII") provides investment advisory services to several venture capital funds including ABPII & AEBPII. The respective GP and managers exercise sole voting & investment powers over the shares held by the foregoing funds. Jean Deleage, Alix Marduel & Farah Champsi (collectively known as the "principals") are managing directors ("md") of ABPII & managers of AEBPII. As md & managers, they may be deemed to share voting & investment powers over the shares held by the funds. The principals disclaim beneficial ownership of all such share held by the foregoing funds, except to the extent of their proportionate pecuniary interests therein.
[F4]Alta Embarcadero BioPharma Partners II, LLC: See footnote for Alta BioPharma Partners II, L.P. on this Form 4.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

RIGEL PHARMACEUTICALS INC

CIK 0001034842

→

Entity typeoperating

IncorporatedDE

Related Parties

filerCIK 0001034842

Filing Metadata

Form type: 4
Filed: Apr 29, 8:00 PM ET
Accepted: Apr 30, 1:48 PM ET
Size: 21.2 KB

View on SEC.gov